LONDON–(BUSINESS WIRE)– #Biotechnology–The global eye infections therapeutics market size is poised to grow by USD 342.39 billion during 2019-2023, according to a new report by Technavio.
Author: Business Wire
Aura Biosciences Announces Clinical Data Presentations at the Upcoming American Academy of Ophthalmology 2019 Annual Meeting
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced multiple data presentations at the upcoming American Academy of Ophthalmology (AAO) 2019 Annual Meeting, be…
Resumen: Synteract amplía el equipo de liderazgo para sus centros de desarrollo especializados en oncología y enfermedades raras
RESEARCH TRIANGLE PARK, Carolina del Norte–(BUSINESS WIRE)–Synteract, una innovadora organización de investigación por contrato (CRO), que trabaja con empresas biotecnológicas y farmacéuticas para comercializar nuevos fármacos, ha contratado a dos lí…
Aldeyra Therapeutics to Present Phase 3 ALLEVIATE Trial Results in Allergic Conjunctivitis at American Academy of Ophthalmology 2019 Annual Meeting
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that it will host an ePoster presentation and discussion of the company’s ALLEVIATE Phase 3 clinical trial of reproxalap in patients with allergic co…
Ocular Therapeutix™ to Present at the 2019 Cantor Global Healthcare Conference
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today an…
Tangible Science and VSP Optics Co-develop New Daily Disposable Silicone Hydrogel Contact Lens
REDWOOD CITY, Calif.–(BUSINESS WIRE)– #contactlenses–Tangible Science and VSP Optics launch Unity BioSync daily disposable silicone hydrogen contact lens featuring modified Tangible Hydra-PEG formula.
Synteract renforce son équipe dirigeante pour les centres de développement de cancérologie et des maladies rares
RESEARCH TRIANGLE PARK, Caroline du Nord–(BUSINESS WIRE)–Synteract, une organisation de recherche sous contrat (ORC) qui s’associe avec des entreprises de biotechnologies et pharmaceutiques pour introduire de nouveaux médicaments sur le marché, a rec…
Synteract erweitert Führungsteam für Entwicklungszentren für Onkologie und seltene Krankheiten
RESEARCH TRIANGLE PARK, North Carolina (USA)–(BUSINESS WIRE)–Synteract, ein innovatives Auftragsforschungsinstitut, das mit Biotech- und Pharmaunternehmen bei der Markteinführung neuer Medikamente zusammenarbeitet, hat zwei erfahrene Führungskräfte e…
Riassunto: Synteract amplia il team dirigenziale per i suoi centri di sviluppo specializzati in oncologia e malattie rare
RESEARCH TRIANGLE PARK, Carolina del Nord–(BUSINESS WIRE)–Synteract, un’innovativa organizzazione di ricerca a contratto (contract research organization, CRO), che collabora con aziende biotecnologiche e case farmaceutiche per il lancio sul mercato d…
Samenvatting: Synteract breidt leiderschapsteam uit voor ontwikkelingscentra oncologie en zeldzame ziekten
RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Synteract, een innovatieve CRO-partnerschap met biotech- en farmaceutische bedrijven om nieuwe geneesmiddelen op de markt te brengen, heeft twee ervaren leiders ingehuurd om zijn Centers of Development in …
SeniorWell Expands Service to Pennsylvania
CHICAGO–(BUSINESS WIRE)–SeniorWell, a mobile healthcare and logistics company, today announced its expansion into Pennsylvania.
Synteract Augments Leadership Team for Oncology and Rare Disease Centers of Development
RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)– #CRO–CRO Synteract is welcoming two experienced leaders to its Centers of Development, Hassan Aly, M.D., Ph.D., for Oncology, & Derek Ansel for Rare/Orphan
Aldeyra Therapeutics to Present at 2019 Cantor Global Healthcare Conference
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today an…
Aerie Pharmaceuticals to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
EyeSouth Expands into Florida Panhandle through Affiliation with the Eye Center of North Florida
ATLANTA–(BUSINESS WIRE)–EyeSouth Partners (“EyeSouth” or the “Company”) is pleased to announce that it has completed an affiliation with the Eye Center of North Florida (“ECNF”). The affiliation represents EyeSouth’s second in Florida and first in th…
North American Optical Microscopes Market by Product, End-user and Country (2019-2027) – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “North America Optical Microscopes Market to 2027 – Regional Analysis and Forecasts by Product, by End User, and Country” report has been added to ResearchAndMarkets.com’s offering. The North America optical microscopes mar…
Aldeyra Therapeutics Receives Fast Track Designation for ADX-2191 for the Prevention of Proliferative Vitreoretinopathy
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to ADX-2191 for the prevention of proliferative vitreoretinopathy…
Ocular Therapeutix™ Announces First Patient Dosed in Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Allergic Conjunctivitis
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today…
NovaBay Pharmaceuticals Receives Approval for Distribution of Avenova in Australia
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces that it has received approval for the distribution of…
GenSight Biologics Reports Sustained Efficacy and Safety at 96 Weeks in RESCUE Phase III Clinical Trial of GS010 for the Treatment of Leber Hereditary Optic Neuropathy (LHON)
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative disease…